Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome
Brief Summary: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a condition that results in long-term bladder and pelvic pain. IC/BPS affects women more often than men. How the disorder develops is not completely known. Bladder instillation is a commonly used treatment in which a mixture of different ingredients are passed into the bladder to help IC/BPS symptoms. There is room to learn more about bladder instillations and which ingredients in them work best. The purpose of this study is to compare the effectiveness of a bladder instillation that contains a steroid (triamcinolone acetonide) to a bladder instillation that does not contain a steroid to treat IC/BPS in women. The study hypothesis is that women with IC/BPS treated with bladder instillations that contain a steroid will have improved outcomes compared to women treated with bladder instillations that do not contain a steroid.


Options:
A: Arm Label: ASP6294; Type: EXPERIMENTAL; Interventions: Drug: ASP6294 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ASP6294; Assigned to Arm(s): ASP6294 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group A: Liposome encapsulated BoNT-A; Type: EXPERIMENTAL; Interventions: Drug: Liposome encapsulated BoNT-A | Arm Label: Group B: BoNT-A 200 U in Normal saline; Type: EXPERIMENTAL; Interventions: Drug: BOTOX 200U in normal saline | Arm Label: Group C: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Liposome encapsulated BoNT-A; Assigned to Arm(s): Group A: Liposome encapsulated BoNT-A | Intervention Type: DRUG; Name: BOTOX 200U in normal saline; Assigned to Arm(s): Group B: BoNT-A 200 U in Normal saline | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Group C: Normal saline
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 1 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 2 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 3 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 5
D: Arm Label: Bladder instillation WITH triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bladder instillation WITH triamcinolone acetonide | Arm Label: Bladder instillation WITHOUT triamcinolone acetonide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bladder instillation WITHOUT triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITH triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITH triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITHOUT triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITHOUT triamcinolone acetonide

Answer: D